We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Brad Kahl

Brad Kahl MD

Professor of Medicine, Washington University School of Medicine; Director, Lymphoma Program, Washington University, St. Louis, Missouri

Dr. Brad S. Kahl is an oncologist in St. Louis who specializes in lymphoma, leukemia, and hematologic malignancies. He is Professor of Medicine in the Division of Oncology at Washington University School of Medicine in St. Louis and is Director of the Lymphoma Program at Washington University. 

Dr. Kahl is a clinical/translational researcher who has published widely and devoted himself to biologic investigations and novel agent development in lymphoma. He has focused efforts into developing effective treatment regimens in older patients with mantle cell lymphoma, including, early in his career, maintenance rituximab and, more currently, the concept of a proteasome inhibitor combined with conventional immunochemotherapy. He has also devoted significant effort to the study of low–tumor burden follicular lymphoma. Beside his specific research in mantle cell and follicular lymphoma, Dr. Kahl has researched novel agents for all types of lymphoma, including bendamustine, ibrutinib, and idelalisib. 

In addition to other professional societies, Dr. Kahl is a member of the American Society of Hematology and the American Society of Clinical Oncology. He is Chair of the ECOG Lymphoma Committee, and serves on the FDA Oncology Drugs Advisory Committee and the NCI Lymphoma Steering Committee, among others. 

Dr. Kahl received his medical degree from Tufts University School of Medicine in Boston and completed residency training at the University of Wisconsin Hospital and Clinics in Madison, where he served as Chief Resident. He also completed his fellowship in hematology at Wisconsin.